

# Press Release

Lund, October 06, 2023

## ***Notice of grant of patent***

**Moroxite T AB announces that the patent application “Novel treatment regimen of cancer” has been granted by a formal notice from European Patent Office (EPO).**

The granted patent relates to a novel composition and administration mode of a particulate material, such as e.g., micro and/or nano sized hydroxyapatite (HA) combined with an antitumor drug (an anthracycline) and an osteoporosis drug (a bisphosphonate).

The patent will be in force at least 20 years from the priority date.

### **For further information, please contact:**

Johan Drott, CEO  
Moroxite T AB  
+46 709-22 41 40  
[johan.drott@moroxitet.com](mailto:johan.drott@moroxitet.com)

### About Moroxite T

Moroxite T is a lifescience company with focus on hindering tumor progression and impeding metastasis. Our novelty lies in a protected carrier platform for cancer therapy using hydroxyapatite for local drug delivery. In Moroxite T, we are committed to developing innovative targeted oncological treatment.